ASCO 2021 | Real-world data on previously untreated MCL in the US and the SHINE study
Michael L. Wang, MD, MD Anderson Cancer Center, Houston, TX, shares the findings of a retrospective study of real-world treatment patterns and outcomes of patients with previously untreated mantle cell lymphoma (MCL) in routine clinical practice in the US. Data from 3455 patients was included in the analysis. Prof. Wang reports that bendamustine-rituximab was the most commonly used first-line treatment and that stem cell transplantation was uncommon, even in elderly patients. Older age and high-risk disease features were found to be predictive of worse outcomes. Prof. Wang comments on these findings. Prof. Wang also highlights the Phase II SHINE study (NCT01776840) which is investigating the addition of the BTK inhibitor ibrutinib to bendamustine and rituximab for newly diagnosed MCL. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
